These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10535883)

  • 1. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response.
    Paterson M; Laxton CD; Thomas HC; Ackrill AM; Foster GR
    Gastroenterology; 1999 Nov; 117(5):1187-97. PubMed ID: 10535883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance.
    Gale MJ; Korth MJ; Katze MG
    Clin Diagn Virol; 1998 Jul; 10(2-3):157-62. PubMed ID: 9741641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner.
    Podevin P; Sabile A; Gajardo R; Delhem N; Abadie A; Lozach PY; Beretta L; Bréchot C
    Hepatology; 2001 Jun; 33(6):1503-11. PubMed ID: 11391540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of interferon signaling by hepatitis C virus non-structural 5A protein: implication of genotypic difference in interferon treatment.
    Kang SM; Won SJ; Lee GH; Lim YS; Hwang SB
    FEBS Lett; 2010 Sep; 584(18):4069-76. PubMed ID: 20804757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication.
    Polyak SJ; Paschal DM; McArdle S; Gale MJ; Moradpour D; Gretch DR
    Hepatology; 1999 Apr; 29(4):1262-71. PubMed ID: 10094974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
    Berg T; Mas Marques A; Höhne M; Wiedenmann B; Hopf U; Schreier E
    Hepatology; 2000 Dec; 32(6):1386-95. PubMed ID: 11093746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism.
    Tsai YH; Kuang WF; Lu TY; Kao JH; Lai MY; Liu CJ; Chen PJ; Hwang LH
    J Hepatol; 2008 Dec; 49(6):899-907. PubMed ID: 18842320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.
    Gale M; Kwieciszewski B; Dossett M; Nakao H; Katze MG
    J Virol; 1999 Aug; 73(8):6506-16. PubMed ID: 10400746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
    Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
    Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner.
    Taguchi T; Nagano-Fujii M; Akutsu M; Kadoya H; Ohgimoto S; Ishido S; Hotta H
    J Gen Virol; 2004 Apr; 85(Pt 4):959-969. PubMed ID: 15039538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells.
    Noguchi T; Satoh S; Noshi T; Hatada E; Fukuda R; Kawai A; Ikeda S; Hijikata M; Shimotohno K
    Microbiol Immunol; 2001; 45(12):829-40. PubMed ID: 11838900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins.
    Aizaki H; Saito S; Ogino T; Miyajima N; Harada T; Matsuura Y; Miyamura T; Kohase M
    J Interferon Cytokine Res; 2000 Dec; 20(12):1111-20. PubMed ID: 11152578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis.
    François C; Duverlie G; Rebouillat D; Khorsi H; Castelain S; Blum HE; Gatignol A; Wychowski C; Moradpour D; Meurs EF
    J Virol; 2000 Jun; 74(12):5587-96. PubMed ID: 10823866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon.
    Song J; Fujii M; Wang F; Itoh M; Hotta H
    J Gen Virol; 1999 Apr; 80 ( Pt 4)():879-886. PubMed ID: 10211956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
    Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
    J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
    World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.